Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hydroxychloroquine × 30 days × Clear all
NCT05576896 2026-06-04

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Northwestern University

Phase 2 Active not recruiting
7 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04523857 2026-05-26

ABBY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
44 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡